Drug Trial Radar · NCT05592990
A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
45
Actual
Start
Jun 14, 2023
Primary completion
Feb 3, 2026
Study completion Feb 3, 2026
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure local and systemic safety and tolerability as well as improvement of Achilles tendon mechanical properties after a single peritendon injection of NGI226 MP in comparison to placebo MP in patients with mid-portion Achilles tendinopathy.
Conditions
- Achilles Tendinopathy
Interventions
NGI226Drug
NGI226 MP
PlaceboDrug
Placebo MP
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with AEs and SAEsTime frame: Up to Day 169 (End of Study)
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Tucson Orthopedic Institute PC
Tucson, Arizona
Advanced Research LLC
Deerfield Beach, Florida
Houston Methodist Hospital
Houston, Texas
Novartis Investigative Site
Caluire-et-Cuire, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hamburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.